Have any thoughts about
Seagen Inc?
Write Note

Operating Margin
Seagen Inc

-32.6%
Current
-16%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-32.6%
=
Operating Profit
-750.5m
/
Revenue
2.3B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Seagen Inc
F:SGT
39.3B EUR
-33%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
312.9B USD
28%
US
Amgen Inc
NASDAQ:AMGN
158B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
30%
NL
argenx SE
XBRU:ARGX
34.8B EUR
-22%
KY
Beigene Ltd
SSE:688235
234.9B CNY
-30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 312.9B USD
Operating Margin
28%
Country US
Market Cap 158B USD
Operating Margin
19%
Country US
Market Cap 119B USD
Operating Margin
40%
Country US
Market Cap 112.8B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.4B AUD
Operating Margin
26%
Country US
Market Cap 82.5B USD
Operating Margin
30%
Country NL
Market Cap 34.8B EUR
Operating Margin
-22%
Country KY
Market Cap 234.9B CNY
Operating Margin
-30%
No Stocks Found

Seagen Inc
Glance View

Market Cap
39.3B EUR
Industry
Biotechnology

Seagen Inc. is a leading biotechnology company focused on developing innovative therapies for cancer treatment using its pioneering antibody-drug conjugate (ADC) technology. Founded in 1998, Seagen's mission is rooted in the belief that targeted therapies can improve the lives of cancer patients. The company has gained attention in the oncology space with its flagship products, such as Adcetris (brentuximab vedotin) and Padcev (enfortumab vedotin), which target specific cancer cells while minimizing damage to healthy tissue. This approach not only enhances efficacy but also helps in reducing side effects commonly associated with traditional chemotherapy. With a strong pipeline of investigational therapies that leverage their ADC platform, Seagen is positioned to be a transformative player in the oncology market. For investors, Seagen represents a compelling opportunity within the biotech sector, especially as demand for effective cancer treatments continues to grow. The company is actively expanding its product portfolio through strategic partnerships and collaborations, bolstering its capabilities in research and development. Financially, Seagen has demonstrated solid sales growth driven by its approved products, and it is continually working towards regulatory approvals for its pipeline candidates. As the landscape of cancer treatment evolves and personalized medicine becomes increasingly important, Seagen's innovative approach and commitment to delivering better patient outcomes make it a company to watch for those interested in the future of oncology and of the broader biotechnology market.

SGT Intrinsic Value
146.35 EUR
Overvaluation 30%
Intrinsic Value
Price
S

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-32.6%
=
Operating Profit
-750.5m
/
Revenue
2.3B
What is the Operating Margin of Seagen Inc?

Based on Seagen Inc's most recent financial statements, the company has Operating Margin of -32.6%.